Alumis Inc

Stock Chart, Company Information, and Scan Results

$27.27(as of Jul 6, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Alumis Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$27.27
Ticker SymbolALMS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees225
CountyUSA
Market Cap$3,378.5M

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc In Our Stock Scanner

As of Jul 07, 2026
As of ---
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.